Leading life sciences venture firm Sofinnova Partners entered into a long-term strategic and financial partnership with Apollo, a high-growth, alternative asset manager looking to expand its presence in the life sciences.

Swiss pharma giant Roche acquired Ireland’s Inflazome and the company’s NLRP3 inflammasome inhibitors aimed at multiple inflammatory diseases.